Katherine Giannamore
    • Labeling & Claims
    • FDA Label Reviews
    • Label & Marketing Reviews
    • Ingredient Reviews
    • Supplement Facts Panels
    • Outer Packaging Requirements
    • Website Reviews
    • Nutrient Content Claims
    • Organic & Natural Claims
    • Structure/Function Claims
    • Disease Claims
    • Health Claims
    • Food, Supplements & Devices
    • FDA Food Services
    • Dietary Supplement Services
    • 30-Day Notification (NDI)
    • 510(k) / Premarket Clearance
    • Premarket Approval (PMA)
    • Imports, Enforcement & General Counsel
    • FDA Imports
    • Warning Letter Responses
    • FDA Consultant Services
  • About
  • Food & Drug Blog
  • Contact
(866) 785-0873 Schedule a Consultation

Tag: Drugs

Marshals Seize Supplements with Undeclared Drug Ingredients

CGMP, Dietary Supplements, Disease Claims, Drugs, Enforcement, FDA, Seizure, Warning LettersFDA

On February 14, 2013, U.S. Marshals, acting on behalf of the U.S. Food and Drug Administration (FDA), raided the headquarters of Globe All Wellness, LLC, a dietary supplement manufacturer based in Hollywood, Florida. Marshals seized what are alleged to be …

Read More

FDA/FTC Issue Joint Warning Letter to Company Marketing Flu Remedy

Disease Claims, Drugs, Enforcement, FDA, FTC, Labeling, Substantiation, Warning LettersFDA, FTC

On January 24, 2013, the U.S. Food and Drug Administration (“FDA”) and the U.S. Federal Trade Commission (“FTC”) issued a joint warning letter to Flu & Cold Defense, LLC (“the Company”), a Florida company, for unlawfully marketing its “GermBullet” inhaler …

Read More

FDA Approves Bladder Control Drug for OTC Use, Highlighting Rx to OTC Switch

Drugs, NDA, OTC Drugs, Rx to OTC SwitchFDA

On January 25, 2013, the U.S. Food and Drug Administration (“FDA”) announced the approval of the first women’s bladder control product available without a doctor’s prescription. In the past, all bladder control drugs were only available by prescription. This product, …

Read More

FDA Targets Online Pharmacies in International Efforts

Drugs, Enforcement, FDA, Medical Devices, Warning LettersFDA

On October 4, 2012, the U.S. Food and Drug Administration (“FDA”) announced that it has taken action as part of an international campaign to protect consumers from illegal online pharmacies. Found here, the FDA’s announcement explains its involvement in the …

Read More

FDA Approves MS Drug, Noting Boxed Warnings

Adverse Events, Boxed Warnings, Drugs, FDA, LabelingFDA

On September 12, 2012, the U.S. Food and Drug Administration (“FDA”) announced the approval of the drug Aubagio (teriflunomide). Manufactured by Sanofi Aventis, Aubagio is a once-a-day tablet for the treatment of relapsing forms of multiple sclerosis (“MS”) in adults. …

Read More

FDA Warns Dietary Supplement Firms for Marketing Concussion Treatments

Dietary Supplements, Disease Claims, Drugs, Food, Labeling, Structure-Function Claims, Warning LettersFDA

On September 6, 2012, the U.S. Food and Drug Administration (“FDA”) issued warning letters to two dietary supplement companies in connection with promoting unapproved products as drugs. According to the FDA, the firms cited by the Agency, PruTect Rx and …

Read More

FDA Approves First Drug Specifically Formulated to Treat Pediatric Tumors

Accelerated Approval Program, Drug, Drugs, FDA, Pediatric, post-marketing studiesFDA

On August 29, 2012, the U.S. Food and Drug Administration (“FDA”) announced the Agency’s approval of a new drug formulated specifically to treat children with a rare type of brain tumor, known as subependymal giant cell astrocytoma (SEGA). Manufactured by …

Read More

FDA Approved Combination Pill for HIV Treatment

Drugs, FDA, HIVFDA

On August 27, 2012, the U.S. Food and Drug Administration (“FDA”) announced the approval of Stribild, a drug intended to treat the HIV-1 infection in adult individuals who have not previously received treatment for the infection. Manufactured by Gilead Sciences, …

Read More

GlaxoSmithKline to Pay $3 Billion in Settlement with Government

Drugs, Enforcement, FDA, GlaxoSmithKline, off-label promotion, off-label use, post-marketing studiesFDA

On July 2, 2012, GlaxoSmithKline (“GSK”) announced its intention to plead guilty in its ongoing healthcare fraud case in what will result in the largest settlement of its kind in the United States. In particular, the pharmaceutical giant will be …

Read More

House Oversight Committee Finds that FDA Actions Cause Drug Shortages

drug shortages, Drugs, Enforcement, FDA, Warning LettersFDA

On June 15, 2012, the U.S. House of Representatives Committee on Oversight and Government Reform issued a Staff Report, detailing the problem of drug shortages for key lifesaving drugs. According to the Report, the shortages are largely affecting the availability …

Read More

Posts pagination

< Page 1 Page 2 Page 3 Page 4 >

    Katherine L. Giannamore
    Rated by Super Lawyers


    loading ...
    Shehadeh Giannamore, PLLC

    Toll-free: (866) 785-0873
    Direct: (305) 507-9843
    Email: contact@giannamore-law.com

    Reachable seven days a week · Response within 24 hours

    Practice Areas

    • Food & Beverage
    • Dietary Supplements
    • Cosmetics & Labeling
    • Medical Devices
    • Drugs & OTC
    • Enforcement & Import Defense

    Popular Services

    • FDA Label Reviews
    • Ingredient Reviews
    • FDA Imports
    • Warning Letter Responses
    • 30-Day NDI Notification

    Firm

    • About
    • Food & Drug Blog
    • Contact
    • Google Reviews

    Information shared on this website and blog is for informational purposes only and may not provide the most up-to-date legal and regulatory information, as we do not provide updates to individual articles after publication. Any commentary or legal analysis herein is for general informational purposes and not to be relied upon for individual legal advice and does not establish an attorney-client relationship.

    © 2026 Shehadeh Giannamore, PLLC. All rights reserved.